Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on August 19, 2026 reporting Item 8.01 (Other Events). KRRO-121 Phase 1/2 trial submission to Australian Alfred Health Human Ethics Committee.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- KRRO-121 Phase 1/2 trial submission to Australian Alfred Health Human Ethics Committee
- GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders
- Trial designed to assess safety, tolerability, pharmacokinetics, and treatment effects
- First-in-human milestone advances Korro’s clinical pipeline but remains subject to ethics approval and enrollment risks
- ClinicalTrials.gov identifier NCT 07773246
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.